Turnstone Biologics Inc.
787 Bank Street, 2nd Floor
Ottawa
Ontario
K1S 3V5
Canada
Tel: 613-421-8930
Website: http://www.turnstonebio.com/
Email: info@turnstonebio.com
About Turnstone Biologics Inc.
Turnstone Biologics is driven by science and innovation, with experienced leadership and world-renowned scientific founders in the field of oncolytics and immunotherapies.
YEAR FOUNDED:
2015
LEADERSHIP:
Founders: Brain Lichty, John Bell, David Stojdl
CEO: Sammy Farah
CTO: Brain Lichty
JOBS:
Please click here for Turnstone Biologics job opportunities.
44 articles about Turnstone Biologics Inc.
-
Turnstone Biologics Expands Scientific Advisory Board with Appointments of Dr. James Mulé and Dr. Eric Tran
12/15/2021
Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, announced the expansion of its Scientific Advisory Board with the appointments of two leaders in the cell therapy field, James Mulé, IPh.D., and Eric Tran, Ph.D.
-
Turnstone Biologics Announces Research Collaboration with Moffitt Cancer Center to Advance Novel TIL Immunotherapies for Solid Tumor Indications
11/29/2021
Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, announced that it has entered into a strategic multi-year research collaboration with Moffitt Cancer Center for pre-clinical development of investigational tumor-infiltrating lymphocyte therapies.
-
New York-based Turnstone Biologics announced it is partnering with the Moffitt Cancer Center to develop tumor-infiltrating lymphocyte (TIL) therapies.
-
Money on the Move: July 21 – 27, 2021
7/28/2021
A quick overview of life science companies scooping up some summer spending money this week. -
Turnstone Biologics Raises $80 Million Series D Financing
7/21/2021
Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, announced the successful completion of an $80 million Series D financing co-led by PFM Health Sciences and Point72.
-
Turnstone Biologics Appoints Stewart Abbot, Ph.D., as Chief Scientific Officer
6/29/2021
Dr Abbot’s appointment further strengthens Turnstone’s senior leadership team, adding depth and expertise in immune cell therapy
-
Turnstone Biologics Announces Executive Leadership Promotions and Board Appointment
5/7/2021
Turnstone Biologics Corp., a clinical-stage biotechnology company focused on the development of cancer immunotherapies, today announced the promotions of José Manuel Otero, Ph.D., to Chief Technology Officer, and Saryah Azmat to Chief Business Officer. Turnstone also announced that Mike Burgess, MB. ChB., Ph.D., will transition from President of R&D to Executive Chairman of R&D and be appointed to the Turnstone Board of Directors
-
SIGA Announces Collaboration with Turnstone Biologics
3/2/2020
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it entered into a collaboration with Turnstone Biologics to provide TPOXX ® (tecovirimat) in connection with Turnstone’s proprietary SKV vaccinia oncolytic immunotherapy platform.
-
BioSpace Movers & Shakers, Jan. 10
1/10/2020
Pharma and biotech companies bolster their executive leadership teams and boards of directors with this week's appointments. -
Turnstone Appoints Saryah Azmat as Senior Vice President of Business Development and Corporate Strategy
1/8/2020
Ms. Azmat will lead identification, evaluation and execution of new business development opportunities and development of the company’s corporate growth strategy.
-
Turnstone Biologics Announces Global Collaboration and License Agreement with Takeda to Develop Novel Viral Immunotherapies
12/19/2019
Turnstone and Takeda to co-develop and co-commercialize RIVAL-01, the lead candidate from Turnstone’s proprietary vaccinia virus platform, with a 50:50 global profit share
-
Although the advent of cell and gene therapies is revolutionizing medicine, it is arguable that the therapies that have been approved to date in this area aren’t living up to expectations.
-
Turnstone Biologics Unveils Novel Vaccinia Oncolytic Viral Immunotherapy Platform
11/30/2018
Groundbreaking Research by Oncolytic Virus Pioneer Dr. John Bell will be Presented at the American Association for Cancer Research Tumor Immunology and Immunotherapy Meeting
-
Turnstone Biologics and the La Jolla Institute for Allergy and Immunology Enter into Strategic Collaboration for Personalized Neoantigen Immunotherapies
9/4/2018
Turnstone Obtaining License to Neoantigen Identification Methodology Developed by the La Jolla Institute.
-
Turnstone Biologics to Present at the 2018 Wedbush PacGrow Healthcare Conference
8/9/2018
Turnstone Biologics announced its presentation at the upcoming investor conference
-
Biotech Movers and Shakers for July 30
7/30/2018
Transition continues as biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those transitions. -
Turnstone Biologics Announces Key Appointments to Senior Leadership Team
7/19/2018
Industry Veteran Jane Pritchett Henderson Named Chief Financial Officer
-
Turnstone Biologics to Present at Jefferies 2018 Global Healthcare Conference
6/1/2018
Turnstone Biologics announced that Sammy Farah, Ph.D., President and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference.
-
Turnstone Biologics Announces U.S. FDA Acceptance of IND for Immunotherapy Targeting HPV Positive Cancers
5/16/2018
Phase I/II clinical trial studying MG1-HPV in combination with anti-PDL1 antibody in patients with cervical, oropharyngeal and other solid tumors to commence in Q2 2018
-
Turnstone Biologics Appoints Dr. Mike Burgess as President of Research and Development
11/15/2017
Dr. Burgess joins from Bristol-Myers Squibb, where he was senior vice president of development across multiple therapeutic areas.